A new cancer treatment protocol utilizing ivermectin has been recently peer-reviewed and is considered a breakthrough publication.
The protocol repurposes Ivermectin, Fenbendazole, and Mebendazole to target mitochondrial-stem cell connection (MCC), a component in the development of stem cancer cells.
According to the protocol, published in the Journal of Orthomolecular Medicine, each of the drugs have anti-cancer effects. Ivermectin “induces autophagy and apoptosis of cancer cell,” the document reads, adding, “In vivo, Ivermectin alone is more effective than standard chemotherapy (gemcitabine) alone at reducing tumor weight and volume in pancreatic cancer.” When given to cancer patients at five times the standard dose for up to 180 days, there were “no serious adverse effects.”
Another family of drugs, Benzimidazoles, from which Fenbendazole and Mebendazole are derived, also show anti-cancer properties. Benzimidazoles induce apoptosis, cell cycle arrest, and target CSCs and metastases.
“Mebendazole was more potent against gastric cancer cell lines than other well-known chemotherapeutic drugs (5-fluorouracil, oxaliplatin, gemcitabine, irinotecan, paclitaxel, cisplatin, etoposide and doxorubicin) in vitro,” the protocol says.
One man described in the protocol received Mebendazole for 19 months. His disease “remained stable,” the document describes, adding that “similar results have been observed with Fenbendazole.”
According to the protocol, three patients with stage IV cancer were “treated at a dose of 1,000 mg three times weekly for several months and experienced complete remission of the disease.” Two of the three patients experienced cancer progression with different lines of treatment prior to Fenbendazole.
“I hope that this peer-reviewed paper lays the groundwork for a brand new future for Cancer Treatment,” cancer researcher William Makis, MD, wrote on X.
